Gut Microbiome Disruption Following SARS-CoV-2: A Review

• Published in: Microorganisms (Basel) Vol. 12; no. 1; p. 131
• Main Authors: Righi, Elda, Dalla Vecchia, Ilaria, Auerbach, Nina, Morra, Matteo, Górska, Anna, Sciammarella, Concetta, Lambertenghi, Lorenza, Gentilotti, Elisa, Mirandola, Massimo, Tacconelli, Evelina, Sartor, Assunta
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01-01-2024; MDPI
• Subjects: beneficial symbionts; Composition; COVID-19; Disease; Genes; Genetic testing; Health aspects; Homeostasis; Infections; Intestinal microflora; Longitudinal studies; Medical personnel; microbiome; Microbiomes; Microbiota; Microbiota (Symbiotic organisms); Opportunist infection; opportunistic pathogens; Pathogenesis; Pathogens; Patients; post-COVID-19 syndrome; Probiotics; Respiratory function; Review; Severe acute respiratory syndrome coronavirus 2; Symbionts; Systematic review; Taxonomy; Italy; France; COVID-19; beneficial symbionts; post-COVID-19 syndrome; microbiome; opportunistic pathogens
• ISSN: 2076-2607; 2076-2607
• DOI: 10.3390/microorganisms12010131

COVID-19 has been associated with having a negative impact on patients' gut microbiome during both active disease and in the post-acute phase. In acute COVID-19, rapid alteration of the gut microbiome composition was observed, showing on one side a reduction in beneficial symbionts (e.g.,
,
) and on the other side an increase in opportunistic pathogens such as
and
. Alpha diversity tends to decrease, especially initially with symptom onset and hospital admission. Although clinical recovery appears to align with improved gut homeostasis, this process could take several weeks, even in mild infections. Moreover, patients with COVID-19 post-acute syndrome showed changes in gut microbiome composition, with specific signatures associated with decreased respiratory function up to 12 months following acute disease. Potential treatments, especially probiotic-based therapy, are under investigation. Open questions remain on the possibility to use gut microbiome data to predict disease progression and on potential confounders that may impair result interpretation (e.g., concomitant therapies in the acute phase; reinfection, vaccines, and occurrence of novel conditions or diseases in the post-acute syndrome). Understanding the relationships between gut microbiome dynamics and disease progression may contribute to better understanding post-COVID syndrome pathogenesis or inform personalized treatment that can affect specific targets or microbiome markers.